查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1988386

栓塞预防器材市场：按产品类型、手术、应用和最终用户划分 - 2026-2032年全球预测

Embolic Protection Devices Market by Product Type, Procedure, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 187 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，栓塞预防设备市场价值将达到 20.2 亿美元，到 2026 年将成长至 21.9 亿美元，到 2032 年将达到 36.4 亿美元，复合年增长率为 8.80%。

主要市场统计数据
基准年 2025 20.2亿美元
预计年份：2026年 21.9亿美元
预测年份 2032 36.4亿美元
复合年增长率 (%) 8.80%

栓塞预防装置的引入说明：重点关注影响装置采用的临床重要性、技术进步和程序考虑因素。

栓塞预防装置已成为现代血管内治疗中不可或缺的辅助工具，可降低远端栓塞的风险，并在介入手术过程中保护脑部和周边微血管。其作用范围涵盖颈动脉置入术、经皮冠状动脉介入治疗和周边动脉介入治疗，在这些手术中，装置的选择、术者技能和病例复杂程度都会影响临床结果。在临床实务中，人们日益认识到栓塞预防并非「一刀切」的解决方案。相反，装置的选择必须考虑病变部位、斑块形态、手术的紧迫性以及解剖结构的限制。

设备工程、影像整合和手术环境的进步如何全面重新定义栓塞预防设备的开发和临床应用。

临床重点、材料科学的进步以及不断发展的手术模式正共同作用，以多项变革性变化重塑栓塞预防领域。滤网孔隙结构和阻塞机制的创新旨在最大限度地提高捕获效率，同时最大限度地减少对血流的干扰，从而提高装置与复杂解剖结构和弯曲血管系统的兼容性。此外，血管内超音波和高解析度血管造影术等先进影像技术的整合，能够更精准地植入装置并即时评估栓塞负荷，从而提高手术准确性和治疗效果。

评估近期美国关税措施如何重塑整个医疗设备生态系统的供应链决策、製造地和商业合约。

2025年美国关税格局对医疗设备产业的製造商和供应商的全球供应链、筹资策略和生产在地化选择都产生了累积影响。关税压力推高了进口零件和成品的实际接收成本，促使原始设备製造商 (OEM) 和零件供应商重新评估筹资策略。为此，一些企业正在加快近岸外包和回流生产，以降低关税波动风险并维持更可预测的前置作业时间。虽然这种转型需要资本投资和营运重组，但从长远来看，它可以降低复杂性。

透过对产品架构、临床应用、治疗环境和最终用户环境进行详细的細項分析，揭示了每种医疗设备。

针对特定细分市场的洞察揭示了产品架构、临床应用、终端用户环境和手术流程如何驱动独特的需求和商业化策略。根据产品类型，此领域可分为复杂机制装置、基于滤网的解决方案和基于闭塞的系统。在基于滤网的技术中，永久性滤网和可回收滤网的设计需要在易用性和长期植入考量之间做出不同的权衡。另一方面，闭塞方法又进一步细分为远端闭塞和近端闭塞策略，以应对不同的解剖结构和栓塞风险。这些产品差异直接影响到实现临床工作流程和医师采纳所需的实证策略。

区域趋势和医疗保健系统差异决定了栓塞预防装置的临床引入、监管准入和供应链策略。

区域趋势影响着法律规范、报销模式、临床实践模式和供应链策略，从而为医疗器材的推广和商业化创造了不同的路径。在美洲，手术量、投资者对器械创新的兴趣以及对临床证据的高度重视，共同推动了先进防护技术的快速普及；与此同时，合约压力和基于价值的采购方式也日益影响着采购决策。在欧洲和中东及非洲地区，监管的异质性和多样化的报销体係要求企业采取适应性强的市场进入策略。临床网路和区域註册库在证明器械在不同医疗基础设施中的有效性方面发挥着至关重要的作用。在亚太地区，基础设施的快速发展、介入治疗能力的不断提升以及政府主导的旨在加强本地製造能力的倡议，正在改变医疗器材的上市和商业性扩张方式。

竞争格局概述，重点在于创新伙伴关係、证据伙伴关係以及公司为实现差异化和拓展业务而采用的策略方法。

栓塞预防器材领域的竞争格局由成熟的医疗设备製造商、小规模专业创新企业以及提供互补技术和组件的策略供应商组成。主要企业透过持续投资于工程、临床证据和扩充性来脱颖而出。他们还将产品改进与实用的培训和支援计划相结合，以确保手术效果的一致性。同时，敏捷的创新者正在推出差异化材料、新型捕获机制和模组化系统设计，以满足特定的临床需求或解决尚未解决的手术难题。

为设备开发人员和销售团队提供实际的策略行动，以加速产品推广，同时加强证据商业化和供应链韧性。

产业领导企业应采取多管齐下的策略，将临床证据、产品设计和商业性执行结合，以加速负责任的推广应用和长期永续性。首先，投资于针对性强的临床项目，重点关注最有价值的适应症和手术场景，确保研究设计能够捕捉到与临床医生和支付方产生共鸣的有意义的终点指标。其次，优先考虑模组化产品开发，以便在不中断现有临床工作流程的情况下逐步升级产品功能，从而降低推广应用的门槛，并促进更广泛的临床接受度。

为了得出基于可靠证据的结论，我们采用了综合调查方法，包括对临床医生的访谈、文献综述、监管审查和供应链分析。

本研究途径结合了与临床和商业相关人员的定性对话，以及对公开临床文献、监管申报文件、临床试验註册资讯和医疗设备附加檔的系统性回顾，以建立可靠的证据基础。研究人员对介入性心臟病专家、血管外科医生、导管检查室管理人员和采购负责人进行了结构化访谈，作为了解医疗设备实际使用模式、手术选择标准和采购决定因素的主要资讯来源。除访谈外，研究人员还咨询了监管专家和契约製造製造商，以了解生产方面的挑战和合规要求。

对成功开发和实施栓塞预防解决方案的临床、技术和商业性要求进行全面概述。

总之，在不断变化的临床需求、医疗机构间手术流程的转变以及材料和影像技术的进步的推动下，栓塞预防器材领域正进入一个实用性创新时期。产品差异化如今取决于能否在最大限度减少手术影响的同时提供临床价值，并拥有可靠的上市后证据和高度灵活的供应链模式。价格趋势和区域监管差异迫使企业进一步优化其采购和商业化策略，以保持竞争力并确保供应的连续性。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章 栓塞预防器材市场：依产品类型划分

  • 复杂机制
  • 筛选类型
    • 永久过滤器
    • 可回收过滤器
  • 闭塞法
    • 远端闭塞
    • 近端闭塞

第九章 依治疗方法分類的栓塞预防器材市场

  • 颈动脉置入术
  • 经皮冠状动脉介入治疗
  • 週边动脉介入治疗

第十章 栓塞预防装置市场：依应用领域划分

  • 颈动脉
    • 无症状性支架置入
    • 症状性支架置入术
  • 冠状动脉
    • 选择性经皮冠状动脉介入治疗
    • 紧急经皮冠状动脉介入治疗
  • 外围
    • 下肢干预
    • 肾臟血管介入治疗

第十一章 栓塞预防设备市场：依最终用户划分

  • 门诊手术中心
  • 心臟导管检查室
  • 医院

第十二章 栓塞预防装置市场：依地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十三章 栓塞预防器材市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十四章 栓塞预防器材市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十五章：美国栓塞预防器材市场

第十六章：中国栓塞预防器材市场

第十七章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Abbott Laboratories
  • AngioDynamics, Inc.
  • Balton Sp. z oo
  • Boston Scientific Corporation
  • Contego Medical, Inc.
  • Cook Group Incorporated
  • Cordis
  • Edwards Lifesciences Corporation
  • Emboline, Inc.
  • Filterlex Medical Ltd.
  • Inari Medical, Inc.
  • InspireMD Inc.
  • Invamed
  • Keystone Heart US, Inc. by Venus Medtech（Hangzhou）Inc.
  • Medtronic PLC
  • Meril Life Sciences Pvt. Ltd.
  • MicroPort Scientific Corporation
  • NIPRO CORPORATION
  • Penumbra, Inc.
  • Protembis GmbH
  • Silk Road Medical, Inc.
  • Stryker Corporation
  • Terumo Medical Corporation
  • Transverse Medical Inc.
  • WL Gore & Associates, Inc.
Product Code: MRR-8958E923A6B8

The Embolic Protection Devices Market was valued at USD 2.02 billion in 2025 and is projected to grow to USD 2.19 billion in 2026, with a CAGR of 8.80%, reaching USD 3.64 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 2.02 billion
Estimated Year [2026] USD 2.19 billion
Forecast Year [2032] USD 3.64 billion
CAGR (%) 8.80%

Contextual introduction to embolic protection devices highlighting clinical importance technological progress and procedural considerations shaping device adoption

Embolic protection devices have become integral adjuncts to contemporary endovascular therapies, reducing distal embolization risk and protecting cerebral and peripheral microvasculature during interventional procedures. Their role spans carotid artery stenting, percutaneous coronary interventions, and peripheral artery interventions, where device selection, operator technique, and case complexity converge to influence clinical outcomes. The clinical community increasingly recognizes that embolic protection is not a one-size-fits-all solution; rather, device choice must reflect lesion location, plaque morphology, procedural urgency, and anatomical constraints.

Advances in device design, imaging integration, and procedural workflows have elevated both expectations and standards for safety and efficacy. At the same time, stakeholders across the care continuum-interventionalists, hospital administrators, and payers-demand robust evidence demonstrating meaningful clinical benefit relative to procedural complexity and cost. Consequently, the ecosystem that supports embolic protection devices now balances engineering innovation with clinical validation and operational practicality. This introduction establishes the clinical context and operational imperatives that underpin the remainder of this executive summary, setting the stage for a structured review of technological shifts, regulatory impacts, segmentation dynamics, regional variations, competitive behavior, and actionable strategies for industry participants.

How advances in device engineering imaging integration and procedural settings are collectively redefining embolic protection device development and clinical use

Several transformative shifts are reshaping the embolic protection landscape, driven by converging clinical priorities, material science progress, and evolving procedural paradigms. Innovations in filter pore architecture and occlusion mechanics have focused on maximizing capture efficiency while minimizing flow disruption, making devices more compatible with complex anatomies and tortuous vasculature. Moreover, the integration of advanced imaging-such as intravascular ultrasound and high-resolution angiography-enables more precise device deployment and real-time assessment of embolic burden, thereby improving procedural confidence and outcomes.

Concurrently, procedural trends influence device demand and design choices. As complex endovascular interventions expand beyond tertiary centers into ambulatory surgical settings and specialized catheterization laboratories, there is increasing pressure to simplify device workflows, reduce procedural time, and ensure reproducible outcomes across operator experience levels. Regulatory pathways have emphasized post-market surveillance and clinical evidence generation, which in turn incentivize companies to invest in registries and comparative studies. These shifts are accelerating the diversification of product portfolios, with manufacturers balancing single-use, retrievable, and occlusion-based solutions to address distinct clinical scenarios. Taken together, these dynamics are creating a more nuanced and capability-driven market that prioritizes clinically demonstrable value and procedural integration.

Assessment of how recent United States tariff measures are reshaping supply chain decisions manufacturing footprints and commercial contracting across the device ecosystem

The 2025 tariff landscape in the United States is exerting a cumulative influence on global supply chains, procurement strategies, and production localization choices for manufacturers and suppliers in the medical device sector. Tariff pressures raise the effective landed cost of imported components and finished goods, prompting OEMs and component suppliers to reevaluate sourcing strategies. In response, some organizations are accelerating nearshoring or reshoring initiatives to mitigate exposure to tariff volatility and to maintain more predictable lead times. This transition requires capital investment and operational restructuring but can reduce complexity in the longer term.

Tariff-induced cost pressure also affects contracting behavior across hospitals, ambulatory surgical centers, and catheterization laboratories. Procurement teams may seek broader supplier diversification or negotiate longer-term agreements to stabilize supply and pricing. Manufacturers, in turn, face choices between absorbing incremental costs, adjusting list pricing, or redesigning products to use alternative components with different sourcing footprints. These commercial decisions occur alongside regulatory and reimbursement considerations, meaning that tariff effects can influence development timelines and market access strategies. Overall, the tariff environment is catalyzing strategic adjustments across sourcing, manufacturing footprint, and commercial contracting that collectively shape how embolic protection device stakeholders navigate cost and continuity of supply.

Deep segmentation analysis connecting product architecture clinical applications procedural contexts and end user environments to reveal differentiated device requirements

Segment-specific insights reveal how product architecture, clinical application, end user environment, and procedural context drive distinct needs and commercialization approaches. Based on product type, the space divides among combined mechanism devices, filter based solutions, and occlusion based systems; within filter based technologies, permanent and retrievable filter designs present different trade-offs between ease of use and long-term implant considerations, while occlusion approaches further bifurcate into distal and proximal occlusion strategies that address different anatomic and embolic risk profiles. These product distinctions directly influence clinical workflows and the associated evidence generation strategies required to achieve physician adoption.

When viewed through the lens of clinical application, devices are applied in carotid, coronary, and peripheral interventions; carotid use cases necessitate differentiation between asymptomatic stenting and symptomatic stenting populations, coronary deployment must account for elective PCI versus emergency PCI contexts where rapid deployment and minimal flow interruption are critical, and peripheral intervention use cases range from lower extremity interventions to targeted renal interventions where vessel size and lesion morphology dictate device selection. End user insights underscore operational realities across ambulatory surgical centers, cardiac catheterization laboratories, and hospitals, each setting presenting distinct procurement processes, staff expertise, and procedural throughput expectations. Finally, procedure-based segmentation-encompassing carotid artery stenting, percutaneous coronary intervention, and peripheral artery intervention-ties the preceding dimensions together, as procedural complexity, patient risk profile, and multidisciplinary coordination shape both technology requirements and clinical outcomes expectations. Understanding these intersecting segmentation layers enables stakeholders to align product design, clinical evidence, and commercialization strategies with the precise demands of specific clinical scenarios.

Regional dynamics and healthcare system differences that determine clinical adoption regulatory access and supply chain strategies for embolic protection devices

Regional dynamics influence regulatory frameworks, reimbursement paradigms, clinical practice patterns, and supply chain strategies, creating differentiated pathways for device adoption and commercialization. In the Americas, procedural volumes, investor interest in device innovation, and a strong emphasis on clinical evidence combine to support rapid introduction of advanced protection technologies, while contracting pressures and value-based procurement increasingly influence purchasing decisions. Moving to Europe, Middle East & Africa, regulatory heterogeneity and varying reimbursement systems require adaptive market access approaches; clinical networks and regional registries play a key role in demonstrating device effectiveness across diverse healthcare infrastructures. In the Asia-Pacific region, rapid infrastructural development, expanding interventional capacity, and government initiatives to enhance local manufacturing capability are changing how devices are brought to market and scaled commercially.

Across these geographies, differences in operator training models, hospital procurement cycles, and the relative balance between public and private healthcare delivery systems affect adoption cadence. Moreover, supply chain considerations-such as component sourcing constraints, logistical complexity, and regional regulatory timelines-create practical drivers for localization strategies. As a result, manufacturers and distributors must tailor clinical evidence generation, pricing approaches, and support models to regional needs while coordinating global product development to capture cross-border learning and efficiencies. This regional nuance underscores the importance of flexible commercialization playbooks that accommodate local regulatory and clinical realities without compromising global quality standards.

Competitive landscape overview emphasizing innovation partnerships evidence generation and strategic pathways companies use to differentiate and scale

Competitive dynamics in the embolic protection device landscape are shaped by a mix of established medical device manufacturers, smaller specialized innovators, and strategic suppliers that provide complementary technologies or components. Leading organizations differentiate through sustained investments in engineering, clinical evidence, and scalability; they pair product enhancements with pragmatic training and support programs to ensure consistent procedural outcomes. At the same time, agile innovators introduce differentiated materials, novel capture mechanisms, and modular system designs that target niche clinical needs or address unmet procedural challenges.

Partnerships and collaborations are central to competitive positioning, whether through co-development arrangements with academic centers that produce robust clinical data or through alliances with contract manufacturers to optimize cost structures and accelerate time-to-market. Mergers and acquisitions remain viable pathways for both market consolidation and rapid capability acquisition, enabling companies to expand portfolios or internalize scarce manufacturing competencies. Distribution strategies also vary, with some players prioritizing direct hospital relationships and others leveraging distributor networks to reach a broader set of end users. Across these approaches, the companies that succeed balance technical differentiation with clear value communication, invest in post-market evidence collection, and maintain flexible supply chain architectures that can respond to regulatory and commercial shifts.

Practical strategic actions for device developers and commercial teams to strengthen evidence commercialization and supply chain resilience while accelerating adoption

Industry leaders should adopt a multi-faceted strategy that aligns clinical evidence, product design, and commercial execution to accelerate responsible adoption and long-term sustainability. First, invest in targeted clinical programs that address the highest-value indications and procedural contexts, ensuring that study designs capture meaningful endpoints that resonate with clinicians and payers. Second, prioritize modular product development that allows incremental feature upgrades without disrupting existing clinical workflows, thereby reducing adoption friction and supporting broader clinical acceptance.

Operationally, strengthen supply chain resilience by identifying alternative suppliers, evaluating nearshoring opportunities, and implementing inventory policies that balance availability with working capital efficiency. Commercial tactics should include tailored go-to-market playbooks for hospitals, catheterization laboratories, and ambulatory surgical centers, with focused training programs that reduce procedural variability and support clinician confidence. Additionally, pursue reimbursement engagement early, aligning clinical evidence with coding and payment pathways to reduce barriers to uptake. Finally, establish strategic partnerships for complementary technologies such as advanced imaging, data analytics, and digital training platforms to enhance procedural value and generate longitudinal outcomes data. By integrating these actions, organizations can improve patient outcomes, reduce operational risk, and create defensible commercial differentiation.

Comprehensive research methodology integrating clinician interviews literature synthesis regulatory review and supply chain analysis to ensure robust evidence-based conclusions

The research approach combined qualitative engagement with clinical and commercial stakeholders and systematic review of publicly available clinical literature, regulatory filings, trial registries, and device labeling to construct a robust evidence foundation. Primary inputs included structured interviews with interventional cardiologists, vascular surgeons, catheterization laboratory managers, and procurement professionals to capture real-world device usage patterns, procedural preferences, and purchasing drivers. These interviews were complemented by consultations with regulatory experts and contract manufacturing representatives to understand manufacturing sensitivities and compliance imperatives.

Secondary research consolidated findings from peer-reviewed clinical studies, registry analyses, and public regulatory documentation to validate trends and identify gaps in evidence. Data synthesis emphasized triangulation across sources to ensure findings reflected both front-line clinical experience and documented outcomes. The methodology also incorporated an assessment of supply chain touchpoints, including component sourcing, logistic pathways, and tariff exposure, to contextualize commercial recommendations. Finally, the research recognized limitations inherent in real-world evidence variability and evolving regulatory guidance, and therefore prioritized transparency about data sources and the confidence assigned to key conclusions.

Concluding synthesis of the clinical technological and commercial imperatives that will guide successful development and adoption of embolic protection solutions

In conclusion, the field of embolic protection devices is experiencing a period of pragmatic innovation driven by evolving clinical needs, procedural migration across care settings, and material and imaging advances. Product differentiation now hinges on the ability to deliver clinical value with minimal procedural disruption, robust post-market evidence, and adaptable supply chain models. Tariff dynamics and regional regulatory diversity further compel companies to refine sourcing and commercialization strategies to maintain competitiveness and supply continuity.

Looking ahead, success will favor organizations that integrate clinical insight into product design, invest in outcome-focused evidence generation, and develop flexible commercial approaches that accommodate the operational realities of hospitals, catheterization laboratories, and ambulatory surgical centers. By combining technical excellence with pragmatic go-to-market execution and resilient manufacturing strategies, stakeholders can improve procedural safety and expand access to embolic protection technologies across diverse healthcare environments.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Embolic Protection Devices Market, by Product Type

  • 8.1. Combined Mechanism
  • 8.2. Filter Based
    • 8.2.1. Permanent Filter
    • 8.2.2. Retrievable Filter
  • 8.3. Occlusion Based
    • 8.3.1. Distal Occlusion
    • 8.3.2. Proximal Occlusion

9. Embolic Protection Devices Market, by Procedure

  • 9.1. Carotid Artery Stenting
  • 9.2. Percutaneous Coronary Intervention
  • 9.3. Peripheral Artery Intervention

10. Embolic Protection Devices Market, by Application

  • 10.1. Carotid
    • 10.1.1. Asymptomatic Stenting
    • 10.1.2. Symptomatic Stenting
  • 10.2. Coronary
    • 10.2.1. Elective Pci
    • 10.2.2. Emergency Pci
  • 10.3. Peripheral
    • 10.3.1. Lower Extremity Intervention
    • 10.3.2. Renal Intervention

11. Embolic Protection Devices Market, by End User

  • 11.1. Ambulatory Surgical Centers
  • 11.2. Cardiac Catheterization Laboratories
  • 11.3. Hospitals

12. Embolic Protection Devices Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Embolic Protection Devices Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Embolic Protection Devices Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Embolic Protection Devices Market

16. China Embolic Protection Devices Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Abbott Laboratories
  • 17.6. AngioDynamics, Inc.
  • 17.7. Balton Sp. z o. o.
  • 17.8. Boston Scientific Corporation
  • 17.9. Contego Medical, Inc.
  • 17.10. Cook Group Incorporated
  • 17.11. Cordis
  • 17.12. Edwards Lifesciences Corporation
  • 17.13. Emboline, Inc.
  • 17.14. Filterlex Medical Ltd.
  • 17.15. Inari Medical, Inc.
  • 17.16. InspireMD Inc.
  • 17.17. Invamed
  • 17.18. Keystone Heart US, Inc. by Venus Medtech (Hangzhou) Inc.
  • 17.19. Medtronic PLC
  • 17.20. Meril Life Sciences Pvt. Ltd.
  • 17.21. MicroPort Scientific Corporation
  • 17.22. NIPRO CORPORATION
  • 17.23. Penumbra, Inc.
  • 17.24. Protembis GmbH
  • 17.25. Silk Road Medical, Inc.
  • 17.26. Stryker Corporation
  • 17.27. Terumo Medical Corporation
  • 17.28. Transverse Medical Inc.
  • 17.29. W. L. Gore & Associates, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL EMBOLIC PROTECTION DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL EMBOLIC PROTECTION DEVICES MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL EMBOLIC PROTECTION DEVICES MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL EMBOLIC PROTECTION DEVICES MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL EMBOLIC PROTECTION DEVICES MARKET SIZE, BY PROCEDURE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL EMBOLIC PROTECTION DEVICES MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL EMBOLIC PROTECTION DEVICES MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL EMBOLIC PROTECTION DEVICES MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL EMBOLIC PROTECTION DEVICES MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL EMBOLIC PROTECTION DEVICES MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES EMBOLIC PROTECTION DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA EMBOLIC PROTECTION DEVICES MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL EMBOLIC PROTECTION DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL EMBOLIC PROTECTION DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL EMBOLIC PROTECTION DEVICES MARKET SIZE, BY COMBINED MECHANISM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL EMBOLIC PROTECTION DEVICES MARKET SIZE, BY COMBINED MECHANISM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL EMBOLIC PROTECTION DEVICES MARKET SIZE, BY COMBINED MECHANISM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL EMBOLIC PROTECTION DEVICES MARKET SIZE, BY FILTER BASED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL EMBOLIC PROTECTION DEVICES MARKET SIZE, BY FILTER BASED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL EMBOLIC PROTECTION DEVICES MARKET SIZE, BY FILTER BASED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL EMBOLIC PROTECTION DEVICES MARKET SIZE, BY FILTER BASED, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL EMBOLIC PROTECTION DEVICES MARKET SIZE, BY PERMANENT FILTER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL EMBOLIC PROTECTION DEVICES MARKET SIZE, BY PERMANENT FILTER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL EMBOLIC PROTECTION DEVICES MARKET SIZE, BY PERMANENT FILTER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL EMBOLIC PROTECTION DEVICES MARKET SIZE, BY RETRIEVABLE FILTER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL EMBOLIC PROTECTION DEVICES MARKET SIZE, BY RETRIEVABLE FILTER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL EMBOLIC PROTECTION DEVICES MARKET SIZE, BY RETRIEVABLE FILTER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL EMBOLIC PROTECTION DEVICES MARKET SIZE, BY OCCLUSION BASED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL EMBOLIC PROTECTION DEVICES MARKET SIZE, BY OCCLUSION BASED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL EMBOLIC PROTECTION DEVICES MARKET SIZE, BY OCCLUSION BASED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL EMBOLIC PROTECTION DEVICES MARKET SIZE, BY OCCLUSION BASED, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL EMBOLIC PROTECTION DEVICES MARKET SIZE, BY DISTAL OCCLUSION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL EMBOLIC PROTECTION DEVICES MARKET SIZE, BY DISTAL OCCLUSION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL EMBOLIC PROTECTION DEVICES MARKET SIZE, BY DISTAL OCCLUSION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL EMBOLIC PROTECTION DEVICES MARKET SIZE, BY PROXIMAL OCCLUSION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL EMBOLIC PROTECTION DEVICES MARKET SIZE, BY PROXIMAL OCCLUSION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL EMBOLIC PROTECTION DEVICES MARKET SIZE, BY PROXIMAL OCCLUSION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL EMBOLIC PROTECTION DEVICES MARKET SIZE, BY PROCEDURE, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL EMBOLIC PROTECTION DEVICES MARKET SIZE, BY CAROTID ARTERY STENTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL EMBOLIC PROTECTION DEVICES MARKET SIZE, BY CAROTID ARTERY STENTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL EMBOLIC PROTECTION DEVICES MARKET SIZE, BY CAROTID ARTERY STENTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL EMBOLIC PROTECTION DEVICES MARKET SIZE, BY PERCUTANEOUS CORONARY INTERVENTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL EMBOLIC PROTECTION DEVICES MARKET SIZE, BY PERCUTANEOUS CORONARY INTERVENTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL EMBOLIC PROTECTION DEVICES MARKET SIZE, BY PERCUTANEOUS CORONARY INTERVENTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL EMBOLIC PROTECTION DEVICES MARKET SIZE, BY PERIPHERAL ARTERY INTERVENTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL EMBOLIC PROTECTION DEVICES MARKET SIZE, BY PERIPHERAL ARTERY INTERVENTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL EMBOLIC PROTECTION DEVICES MARKET SIZE, BY PERIPHERAL ARTERY INTERVENTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL EMBOLIC PROTECTION DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL EMBOLIC PROTECTION DEVICES MARKET SIZE, BY CAROTID, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL EMBOLIC PROTECTION DEVICES MARKET SIZE, BY CAROTID, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL EMBOLIC PROTECTION DEVICES MARKET SIZE, BY CAROTID, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL EMBOLIC PROTECTION DEVICES MARKET SIZE, BY CAROTID, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL EMBOLIC PROTECTION DEVICES MARKET SIZE, BY ASYMPTOMATIC STENTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL EMBOLIC PROTECTION DEVICES MARKET SIZE, BY ASYMPTOMATIC STENTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL EMBOLIC PROTECTION DEVICES MARKET SIZE, BY ASYMPTOMATIC STENTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL EMBOLIC PROTECTION DEVICES MARKET SIZE, BY SYMPTOMATIC STENTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL EMBOLIC PROTECTION DEVICES MARKET SIZE, BY SYMPTOMATIC STENTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL EMBOLIC PROTECTION DEVICES MARKET SIZE, BY SYMPTOMATIC STENTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL EMBOLIC PROTECTION DEVICES MARKET SIZE, BY CORONARY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL EMBOLIC PROTECTION DEVICES MARKET SIZE, BY CORONARY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL EMBOLIC PROTECTION DEVICES MARKET SIZE, BY CORONARY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL EMBOLIC PROTECTION DEVICES MARKET SIZE, BY CORONARY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL EMBOLIC PROTECTION DEVICES MARKET SIZE, BY ELECTIVE PCI, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL EMBOLIC PROTECTION DEVICES MARKET SIZE, BY ELECTIVE PCI, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL EMBOLIC PROTECTION DEVICES MARKET SIZE, BY ELECTIVE PCI, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL EMBOLIC PROTECTION DEVICES MARKET SIZE, BY EMERGENCY PCI, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL EMBOLIC PROTECTION DEVICES MARKET SIZE, BY EMERGENCY PCI, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL EMBOLIC PROTECTION DEVICES MARKET SIZE, BY EMERGENCY PCI, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL EMBOLIC PROTECTION DEVICES MARKET SIZE, BY PERIPHERAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL EMBOLIC PROTECTION DEVICES MARKET SIZE, BY PERIPHERAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL EMBOLIC PROTECTION DEVICES MARKET SIZE, BY PERIPHERAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL EMBOLIC PROTECTION DEVICES MARKET SIZE, BY PERIPHERAL, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL EMBOLIC PROTECTION DEVICES MARKET SIZE, BY LOWER EXTREMITY INTERVENTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL EMBOLIC PROTECTION DEVICES MARKET SIZE, BY LOWER EXTREMITY INTERVENTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL EMBOLIC PROTECTION DEVICES MARKET SIZE, BY LOWER EXTREMITY INTERVENTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL EMBOLIC PROTECTION DEVICES MARKET SIZE, BY RENAL INTERVENTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL EMBOLIC PROTECTION DEVICES MARKET SIZE, BY RENAL INTERVENTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL EMBOLIC PROTECTION DEVICES MARKET SIZE, BY RENAL INTERVENTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL EMBOLIC PROTECTION DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL EMBOLIC PROTECTION DEVICES MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL EMBOLIC PROTECTION DEVICES MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL EMBOLIC PROTECTION DEVICES MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL EMBOLIC PROTECTION DEVICES MARKET SIZE, BY CARDIAC CATHETERIZATION LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL EMBOLIC PROTECTION DEVICES MARKET SIZE, BY CARDIAC CATHETERIZATION LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL EMBOLIC PROTECTION DEVICES MARKET SIZE, BY CARDIAC CATHETERIZATION LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL EMBOLIC PROTECTION DEVICES MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL EMBOLIC PROTECTION DEVICES MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL EMBOLIC PROTECTION DEVICES MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL EMBOLIC PROTECTION DEVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. AMERICAS EMBOLIC PROTECTION DEVICES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 79. AMERICAS EMBOLIC PROTECTION DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 80. AMERICAS EMBOLIC PROTECTION DEVICES MARKET SIZE, BY FILTER BASED, 2018-2032 (USD MILLION)
  • TABLE 81. AMERICAS EMBOLIC PROTECTION DEVICES MARKET SIZE, BY OCCLUSION BASED, 2018-2032 (USD MILLION)
  • TABLE 82. AMERICAS EMBOLIC PROTECTION DEVICES MARKET SIZE, BY PROCEDURE, 2018-2032 (USD MILLION)
  • TABLE 83. AMERICAS EMBOLIC PROTECTION DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 84. AMERICAS EMBOLIC PROTECTION DEVICES MARKET SIZE, BY CAROTID, 2018-2032 (USD MILLION)
  • TABLE 85. AMERICAS EMBOLIC PROTECTION DEVICES MARKET SIZE, BY CORONARY, 2018-2032 (USD MILLION)
  • TABLE 86. AMERICAS EMBOLIC PROTECTION DEVICES MARKET SIZE, BY PERIPHERAL, 2018-2032 (USD MILLION)
  • TABLE 87. AMERICAS EMBOLIC PROTECTION DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 88. NORTH AMERICA EMBOLIC PROTECTION DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. NORTH AMERICA EMBOLIC PROTECTION DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 90. NORTH AMERICA EMBOLIC PROTECTION DEVICES MARKET SIZE, BY FILTER BASED, 2018-2032 (USD MILLION)
  • TABLE 91. NORTH AMERICA EMBOLIC PROTECTION DEVICES MARKET SIZE, BY OCCLUSION BASED, 2018-2032 (USD MILLION)
  • TABLE 92. NORTH AMERICA EMBOLIC PROTECTION DEVICES MARKET SIZE, BY PROCEDURE, 2018-2032 (USD MILLION)
  • TABLE 93. NORTH AMERICA EMBOLIC PROTECTION DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 94. NORTH AMERICA EMBOLIC PROTECTION DEVICES MARKET SIZE, BY CAROTID, 2018-2032 (USD MILLION)
  • TABLE 95. NORTH AMERICA EMBOLIC PROTECTION DEVICES MARKET SIZE, BY CORONARY, 2018-2032 (USD MILLION)
  • TABLE 96. NORTH AMERICA EMBOLIC PROTECTION DEVICES MARKET SIZE, BY PERIPHERAL, 2018-2032 (USD MILLION)
  • TABLE 97. NORTH AMERICA EMBOLIC PROTECTION DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 98. LATIN AMERICA EMBOLIC PROTECTION DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. LATIN AMERICA EMBOLIC PROTECTION DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 100. LATIN AMERICA EMBOLIC PROTECTION DEVICES MARKET SIZE, BY FILTER BASED, 2018-2032 (USD MILLION)
  • TABLE 101. LATIN AMERICA EMBOLIC PROTECTION DEVICES MARKET SIZE, BY OCCLUSION BASED, 2018-2032 (USD MILLION)
  • TABLE 102. LATIN AMERICA EMBOLIC PROTECTION DEVICES MARKET SIZE, BY PROCEDURE, 2018-2032 (USD MILLION)
  • TABLE 103. LATIN AMERICA EMBOLIC PROTECTION DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 104. LATIN AMERICA EMBOLIC PROTECTION DEVICES MARKET SIZE, BY CAROTID, 2018-2032 (USD MILLION)
  • TABLE 105. LATIN AMERICA EMBOLIC PROTECTION DEVICES MARKET SIZE, BY CORONARY, 2018-2032 (USD MILLION)
  • TABLE 106. LATIN AMERICA EMBOLIC PROTECTION DEVICES MARKET SIZE, BY PERIPHERAL, 2018-2032 (USD MILLION)
  • TABLE 107. LATIN AMERICA EMBOLIC PROTECTION DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 108. EUROPE, MIDDLE EAST & AFRICA EMBOLIC PROTECTION DEVICES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 109. EUROPE, MIDDLE EAST & AFRICA EMBOLIC PROTECTION DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 110. EUROPE, MIDDLE EAST & AFRICA EMBOLIC PROTECTION DEVICES MARKET SIZE, BY FILTER BASED, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPE, MIDDLE EAST & AFRICA EMBOLIC PROTECTION DEVICES MARKET SIZE, BY OCCLUSION BASED, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPE, MIDDLE EAST & AFRICA EMBOLIC PROTECTION DEVICES MARKET SIZE, BY PROCEDURE, 2018-2032 (USD MILLION)
  • TABLE 113. EUROPE, MIDDLE EAST & AFRICA EMBOLIC PROTECTION DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPE, MIDDLE EAST & AFRICA EMBOLIC PROTECTION DEVICES MARKET SIZE, BY CAROTID, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPE, MIDDLE EAST & AFRICA EMBOLIC PROTECTION DEVICES MARKET SIZE, BY CORONARY, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPE, MIDDLE EAST & AFRICA EMBOLIC PROTECTION DEVICES MARKET SIZE, BY PERIPHERAL, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPE, MIDDLE EAST & AFRICA EMBOLIC PROTECTION DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPE EMBOLIC PROTECTION DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 119. EUROPE EMBOLIC PROTECTION DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 120. EUROPE EMBOLIC PROTECTION DEVICES MARKET SIZE, BY FILTER BASED, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPE EMBOLIC PROTECTION DEVICES MARKET SIZE, BY OCCLUSION BASED, 2018-2032 (USD MILLION)
  • TABLE 122. EUROPE EMBOLIC PROTECTION DEVICES MARKET SIZE, BY PROCEDURE, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPE EMBOLIC PROTECTION DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPE EMBOLIC PROTECTION DEVICES MARKET SIZE, BY CAROTID, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPE EMBOLIC PROTECTION DEVICES MARKET SIZE, BY CORONARY, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPE EMBOLIC PROTECTION DEVICES MARKET SIZE, BY PERIPHERAL, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPE EMBOLIC PROTECTION DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 128. MIDDLE EAST EMBOLIC PROTECTION DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 129. MIDDLE EAST EMBOLIC PROTECTION DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 130. MIDDLE EAST EMBOLIC PROTECTION DEVICES MARKET SIZE, BY FILTER BASED, 2018-2032 (USD MILLION)
  • TABLE 131. MIDDLE EAST EMBOLIC PROTECTION DEVICES MARKET SIZE, BY OCCLUSION BASED, 2018-2032 (USD MILLION)
  • TABLE 132. MIDDLE EAST EMBOLIC PROTECTION DEVICES MARKET SIZE, BY PROCEDURE, 2018-2032 (USD MILLION)
  • TABLE 133. MIDDLE EAST EMBOLIC PROTECTION DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 134. MIDDLE EAST EMBOLIC PROTECTION DEVICES MARKET SIZE, BY CAROTID, 2018-2032 (USD MILLION)
  • TABLE 135. MIDDLE EAST EMBOLIC PROTECTION DEVICES MARKET SIZE, BY CORONARY, 2018-2032 (USD MILLION)
  • TABLE 136. MIDDLE EAST EMBOLIC PROTECTION DEVICES MARKET SIZE, BY PERIPHERAL, 2018-2032 (USD MILLION)
  • TABLE 137. MIDDLE EAST EMBOLIC PROTECTION DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 138. AFRICA EMBOLIC PROTECTION DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 139. AFRICA EMBOLIC PROTECTION DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 140. AFRICA EMBOLIC PROTECTION DEVICES MARKET SIZE, BY FILTER BASED, 2018-2032 (USD MILLION)
  • TABLE 141. AFRICA EMBOLIC PROTECTION DEVICES MARKET SIZE, BY OCCLUSION BASED, 2018-2032 (USD MILLION)
  • TABLE 142. AFRICA EMBOLIC PROTECTION DEVICES MARKET SIZE, BY PROCEDURE, 2018-2032 (USD MILLION)
  • TABLE 143. AFRICA EMBOLIC PROTECTION DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 144. AFRICA EMBOLIC PROTECTION DEVICES MARKET SIZE, BY CAROTID, 2018-2032 (USD MILLION)
  • TABLE 145. AFRICA EMBOLIC PROTECTION DEVICES MARKET SIZE, BY CORONARY, 2018-2032 (USD MILLION)
  • TABLE 146. AFRICA EMBOLIC PROTECTION DEVICES MARKET SIZE, BY PERIPHERAL, 2018-2032 (USD MILLION)
  • TABLE 147. AFRICA EMBOLIC PROTECTION DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 148. ASIA-PACIFIC EMBOLIC PROTECTION DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 149. ASIA-PACIFIC EMBOLIC PROTECTION DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 150. ASIA-PACIFIC EMBOLIC PROTECTION DEVICES MARKET SIZE, BY FILTER BASED, 2018-2032 (USD MILLION)
  • TABLE 151. ASIA-PACIFIC EMBOLIC PROTECTION DEVICES MARKET SIZE, BY OCCLUSION BASED, 2018-2032 (USD MILLION)
  • TABLE 152. ASIA-PACIFIC EMBOLIC PROTECTION DEVICES MARKET SIZE, BY PROCEDURE, 2018-2032 (USD MILLION)
  • TABLE 153. ASIA-PACIFIC EMBOLIC PROTECTION DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 154. ASIA-PACIFIC EMBOLIC PROTECTION DEVICES MARKET SIZE, BY CAROTID, 2018-2032 (USD MILLION)
  • TABLE 155. ASIA-PACIFIC EMBOLIC PROTECTION DEVICES MARKET SIZE, BY CORONARY, 2018-2032 (USD MILLION)
  • TABLE 156. ASIA-PACIFIC EMBOLIC PROTECTION DEVICES MARKET SIZE, BY PERIPHERAL, 2018-2032 (USD MILLION)
  • TABLE 157. ASIA-PACIFIC EMBOLIC PROTECTION DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 158. GLOBAL EMBOLIC PROTECTION DEVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 159. ASEAN EMBOLIC PROTECTION DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 160. ASEAN EMBOLIC PROTECTION DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 161. ASEAN EMBOLIC PROTECTION DEVICES MARKET SIZE, BY FILTER BASED, 2018-2032 (USD MILLION)
  • TABLE 162. ASEAN EMBOLIC PROTECTION DEVICES MARKET SIZE, BY OCCLUSION BASED, 2018-2032 (USD MILLION)
  • TABLE 163. ASEAN EMBOLIC PROTECTION DEVICES MARKET SIZE, BY PROCEDURE, 2018-2032 (USD MILLION)
  • TABLE 164. ASEAN EMBOLIC PROTECTION DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 165. ASEAN EMBOLIC PROTECTION DEVICES MARKET SIZE, BY CAROTID, 2018-2032 (USD MILLION)
  • TABLE 166. ASEAN EMBOLIC PROTECTION DEVICES MARKET SIZE, BY CORONARY, 2018-2032 (USD MILLION)
  • TABLE 167. ASEAN EMBOLIC PROTECTION DEVICES MARKET SIZE, BY PERIPHERAL, 2018-2032 (USD MILLION)
  • TABLE 168. ASEAN EMBOLIC PROTECTION DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 169. GCC EMBOLIC PROTECTION DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 170. GCC EMBOLIC PROTECTION DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 171. GCC EMBOLIC PROTECTION DEVICES MARKET SIZE, BY FILTER BASED, 2018-2032 (USD MILLION)
  • TABLE 172. GCC EMBOLIC PROTECTION DEVICES MARKET SIZE, BY OCCLUSION BASED, 2018-2032 (USD MILLION)
  • TABLE 173. GCC EMBOLIC PROTECTION DEVICES MARKET SIZE, BY PROCEDURE, 2018-2032 (USD MILLION)
  • TABLE 174. GCC EMBOLIC PROTECTION DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 175. GCC EMBOLIC PROTECTION DEVICES MARKET SIZE, BY CAROTID, 2018-2032 (USD MILLION)
  • TABLE 176. GCC EMBOLIC PROTECTION DEVICES MARKET SIZE, BY CORONARY, 2018-2032 (USD MILLION)
  • TABLE 177. GCC EMBOLIC PROTECTION DEVICES MARKET SIZE, BY PERIPHERAL, 2018-2032 (USD MILLION)
  • TABLE 178. GCC EMBOLIC PROTECTION DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 179. EUROPEAN UNION EMBOLIC PROTECTION DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 180. EUROPEAN UNION EMBOLIC PROTECTION DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 181. EUROPEAN UNION EMBOLIC PROTECTION DEVICES MARKET SIZE, BY FILTER BASED, 2018-2032 (USD MILLION)
  • TABLE 182. EUROPEAN UNION EMBOLIC PROTECTION DEVICES MARKET SIZE, BY OCCLUSION BASED, 2018-2032 (USD MILLION)
  • TABLE 183. EUROPEAN UNION EMBOLIC PROTECTION DEVICES MARKET SIZE, BY PROCEDURE, 2018-2032 (USD MILLION)
  • TABLE 184. EUROPEAN UNION EMBOLIC PROTECTION DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 185. EUROPEAN UNION EMBOLIC PROTECTION DEVICES MARKET SIZE, BY CAROTID, 2018-2032 (USD MILLION)
  • TABLE 186. EUROPEAN UNION EMBOLIC PROTECTION DEVICES MARKET SIZE, BY CORONARY, 2018-2032 (USD MILLION)
  • TABLE 187. EUROPEAN UNION EMBOLIC PROTECTION DEVICES MARKET SIZE, BY PERIPHERAL, 2018-2032 (USD MILLION)
  • TABLE 188. EUROPEAN UNION EMBOLIC PROTECTION DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 189. BRICS EMBOLIC PROTECTION DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 190. BRICS EMBOLIC PROTECTION DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 191. BRICS EMBOLIC PROTECTION DEVICES MARKET SIZE, BY FILTER BASED, 2018-2032 (USD MILLION)
  • TABLE 192. BRICS EMBOLIC PROTECTION DEVICES MARKET SIZE, BY OCCLUSION BASED, 2018-2032 (USD MILLION)
  • TABLE 193. BRICS EMBOLIC PROTECTION DEVICES MARKET SIZE, BY PROCEDURE, 2018-2032 (USD MILLION)
  • TABLE 194. BRICS EMBOLIC PROTECTION DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 195. BRICS EMBOLIC PROTECTION DEVICES MARKET SIZE, BY CAROTID, 2018-2032 (USD MILLION)
  • TABLE 196. BRICS EMBOLIC PROTECTION DEVICES MARKET SIZE, BY CORONARY, 2018-2032 (USD MILLION)
  • TABLE 197. BRICS EMBOLIC PROTECTION DEVICES MARKET SIZE, BY PERIPHERAL, 2018-2032 (USD MILLION)
  • TABLE 198. BRICS EMBOLIC PROTECTION DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 199. G7 EMBOLIC PROTECTION DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 200. G7 EMBOLIC PROTECTION DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 201. G7 EMBOLIC PROTECTION DEVICES MARKET SIZE, BY FILTER BASED, 2018-2032 (USD MILLION)
  • TABLE 202. G7 EMBOLIC PROTECTION DEVICES MARKET SIZE, BY OCCLUSION BASED, 2018-2032 (USD MILLION)
  • TABLE 203. G7 EMBOLIC PROTECTION DEVICES MARKET SIZE, BY PROCEDURE, 2018-2032 (USD MILLION)
  • TABLE 204. G7 EMBOLIC PROTECTION DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 205. G7 EMBOLIC PROTECTION DEVICES MARKET SIZE, BY CAROTID, 2018-2032 (USD MILLION)
  • TABLE 206. G7 EMBOLIC PROTECTION DEVICES MARKET SIZE, BY CORONARY, 2018-2032 (USD MILLION)
  • TABLE 207. G7 EMBOLIC PROTECTION DEVICES MARKET SIZE, BY PERIPHERAL, 2018-2032 (USD MILLION)
  • TABLE 208. G7 EMBOLIC PROTECTION DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 209. NATO EMBOLIC PROTECTION DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 210. NATO EMBOLIC PROTECTION DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 211. NATO EMBOLIC PROTECTION DEVICES MARKET SIZE, BY FILTER BASED, 2018-2032 (USD MILLION)
  • TABLE 212. NATO EMBOLIC PROTECTION DEVICES MARKET SIZE, BY OCCLUSION BASED, 2018-2032 (USD MILLION)
  • TABLE 213. NATO EMBOLIC PROTECTION DEVICES MARKET SIZE, BY PROCEDURE, 2018-2032 (USD MILLION)
  • TABLE 214. NATO EMBOLIC PROTECTION DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 215. NATO EMBOLIC PROTECTION DEVICES MARKET SIZE, BY CAROTID, 2018-2032 (USD MILLION)
  • TABLE 216. NATO EMBOLIC PROTECTION DEVICES MARKET SIZE, BY CORONARY, 2018-2032 (USD MILLION)
  • TABLE 217. NATO EMBOLIC PROTECTION DEVICES MARKET SIZE, BY PERIPHERAL, 2018-2032 (USD MILLION)
  • TABLE 218. NATO EMBOLIC PROTECTION DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 219. GLOBAL EMBOLIC PROTECTION DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 220. UNITED STATES EMBOLIC PROTECTION DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 221. UNITED STATES EMBOLIC PROTECTION DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 222. UNITED STATES EMBOLIC PROTECTION DEVICES MARKET SIZE, BY FILTER BASED, 2018-2032 (USD MILLION)
  • TABLE 223. UNITED STATES EMBOLIC PROTECTION DEVICES MARKET SIZE, BY OCCLUSION BASED, 2018-2032 (USD MILLION)
  • TABLE 224. UNITED STATES EMBOLIC PROTECTION DEVICES MARKET SIZE, BY PROCEDURE, 2018-2032 (USD MILLION)
  • TABLE 225. UNITED STATES EMBOLIC PROTECTION DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 226. UNITED STATES EMBOLIC PROTECTION DEVICES MARKET SIZE, BY CAROTID, 2018-2032 (USD MILLION)
  • TABLE 227. UNITED STATES EMBOLIC PROTECTION DEVICES MARKET SIZE, BY CORONARY, 2018-2032 (USD MILLION)
  • TABLE 228. UNITED STATES EMBOLIC PROTECTION DEVICES MARKET SIZE, BY PERIPHERAL, 2018-2032 (USD MILLION)
  • TABLE 229. UNITED STATES EMBOLIC PROTECTION DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 230. CHINA EMBOLIC PROTECTION DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 231. CHINA EMBOLIC PROTECTION DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 232. CHINA EMBOLIC PROTECTION DEVICES MARKET SIZE, BY FILTER BASED, 2018-2032 (USD MILLION)
  • TABLE 233. CHINA EMBOLIC PROTECTION DEVICES MARKET SIZE, BY OCCLUSION BASED, 2018-2032 (USD MILLION)
  • TABLE 234. CHINA EMBOLIC PROTECTION DEVICES MARKET SIZE, BY PROCEDURE, 2018-2032 (USD MILLION)
  • TABLE 235. CHINA EMBOLIC PROTECTION DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 236. CHINA EMBOLIC PROTECTION DEVICES MARKET SIZE, BY CAROTID, 2018-2032 (USD MILLION)
  • TABLE 237. CHINA EMBOLIC PROTECTION DEVICES MARKET SIZE, BY CORONARY, 2018-2032 (USD MILLION)
  • TABLE 238. CHINA EMBOLIC PROTECTION DEVICES MARKET SIZE, BY PERIPHERAL, 2018-2032 (USD MILLION)
  • TABLE 239. CHINA EMBOLIC PROTECTION DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)